# CORT catalysts: CORCEPT THERAPEUTICS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cort/catalysts

> CORCEPT THERAPEUTICS INC (CORT) has 8 upcoming catalysts. The next is the Lifyorli™ (relacorilant) primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | CORCEPT THERAPEUTICS INC |
| Ticker | CORT (Nasdaq) |
| SEC CIK | 1088856 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/cort |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 30, 2024 | [Corcept NDA/BLA submission](https://sec-api.dev/pdufa/corcept) | CORT | severe endocrinologic, oncologic, metabolic and neurologic disorders | completed | "REDWOOD CITY, Calif., (December 30, 2024)  Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000119312524286917/d834253dex991.htm)) |
| December 30, 2024 | [Lifyorli™ (relacorilant) NDA/BLA submission](https://sec-api.dev/pdufa/relacorilant) | CORT | endogenous hypercortisolism | completed | "On December 30, 2024, we submitted to the United States Food and Drug Administration ("FDA") a New Drug Application ("NDA") for a proprietary cortisol modulator we have developed, relacorilant, that, like Korlym, modulates the effects of cortisol by binding at the GR, but has no affinity for the PR and so does not cause PR-related side effects." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1088856/000162828025008167/cort-20241231.htm)) |
| February 26, 2025 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "REDWOOD CITY, Calif., (February 26, 2025) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828025008131/exhibit991pressrelease02-2.htm)) |
| March 3, 2025 | [Corcept NDA/BLA submission](https://sec-api.dev/pdufa/corcept) | CORT | with endogenous hypercortisolism | completed | "On March 3, 2025, Corcept Therapeutics Incorporated (the "Company") issued a press release announcing that the U.S. Food and Drug Administration filed the Company's New Drug Application submission for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing's syndrome)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1088856/000119312525044123/d914293d8k.htm)) |
| Apr 2025 | [Lifyorli™ (relacorilant) trial start](https://sec-api.dev/pdufa/relacorilant) | CORT |  | completed | "In April 2025, we initiated BELLA, an open-label Phase 2 trial with three parts." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1088856/000162828026050613/cort-20260630.htm)) |
| May 5, 2025 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828025022167/exhibit991pressrelease0505.htm)) |
| July 14, 2025 | [Corcept NDA/BLA submission](https://sec-api.dev/pdufa/corcept) | CORT | severe endocrinologic, oncologic, metabolic and neurologic disorders | completed | "REDWOOD CITY, Calif., (July 14, 2025)  Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000119312525158454/d940113dex991.htm)) |
| July 31, 2025 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828025036999/exhibit991pressrelease07-3.htm)) |
| September 10, 2025 | [Corcept NDA/BLA acceptance](https://sec-api.dev/pdufa/corcept) | CORT | platinum-resistant ovarian cancer | completed | "On September 10, 2025, Corcept Therapeutics Incorporated (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1088856/000119312525199706/d947259d8k.htm)) |
| November 4, 2025 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/cort110425ex991pressrelease.htm)) |
| Dec 2025 | [Opdivo® (nivolumab) trial start](https://sec-api.dev/pdufa/nivolumab) | CORT |  | completed | "In December 2025, we initiated a Phase 1b trial, SYNERGY, with a planned enrollment of 30 patients with solid tumors to evaluate the efficacy and safety of treatment with nenocorilant plus nivolumab (a PD-1 checkpoint inhibitor)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1088856/000162828026028902/cort-20260331.htm)) |
| December 30, 2025 | [Corcept PDUFA date](https://sec-api.dev/pdufa/corcept) | CORT |  | completed, complete response letter | "FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000119312525044123/d914293dex991.htm)) |
| December 30, 2025 | [Lifyorli™ (relacorilant) PDUFA date](https://sec-api.dev/pdufa/relacorilant) | CORT | hypercortisolism | scheduled | ""Our New Drug Application (NDA) for relacorilant in hypercortisolism has a Prescription Drug User Fee Act (PDUFA) date of December 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/cort110425ex991pressrelease.htm)) |
| December 31, 2025 | [Corcept complete response letter (CRL)](https://sec-api.dev/pdufa/corcept) | CORT | hypertension secondary to hypercortisolism | completed, complete response letter | "On December 31, 2025, Corcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1088856/000119312525338184/d50993d8k.htm)) |
| January 28, 2026 | [Nda219398 complete response letter (CRL)](https://sec-api.dev/pdufa/nda219398) | CORT |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219398_20260128.pdf%22)) |
| February 13, 2026 | [Miricorilant (cohort a) primary completion](https://sec-api.dev/pdufa/miricorilant-cohort-a) | CORT |  | completed | "NCT06108219 (A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-13 (ACTUAL); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06108219)) |
| February 24, 2026 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort022426ex991pressrelease.htm)) |
| Mar 2026 | [Lifyorli™ (relacorilant) FDA approval](https://sec-api.dev/pdufa/relacorilant) | CORT | with platinum-resistant ovarian cancer in March 2026 | completed, approved | "•FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer in March 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/cort072926ex991pressrelease.htm)) |
| March 25, 2026 | [Corcept FDA approval](https://sec-api.dev/pdufa/corcept) | CORT | with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer | completed, approved | "On March 25, 2026, Corcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1088856/000119312526123543/d123475d8k.htm)) |
| March 25, 2026 | [TAXOL® (paclitaxel) FDA approval](https://sec-api.dev/pdufa/paclitaxel) | CORT | severe endocrinologic, oncologic, metabolic and neurologic disorders | completed, approved | "Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000119312526123543/d123475dex991.htm)) |
| Apr 2026 | [Lifyorli™ (relacorilant) NDA/BLA submission](https://sec-api.dev/pdufa/relacorilant) | CORT |  | completed | "Rather than requiring additional evidence, however, at the customary post-CRL meeting held in April 2026, the FDA asked for additional analyses of the data already submitted as part of our NDA - specifically, a global statistical test ("GST") of relacorilant's effect on three of the most common and serious symptoms of Cushing's syndrome - hypertension, hyperglycemia and excess body weight." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1088856/000162828026069501/cort-20260930.htm)) |
| April 30, 2026 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026028892/cort043026ex991pressrelease.htm)) |
| June 17, 2026 | [Corcept NDA/BLA submission](https://sec-api.dev/pdufa/corcept) | CORT | Cushing's syndrome | completed | "On June 17, 2026, Corcept Therapeutics Incorporated (the "Company") issued a press release announcing that the Company has resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushing's syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1088856/000119312526274258/d159941d8k.htm)) |
| June 17, 2026 | [Lifyorli™ (relacorilant) NDA/BLA submission](https://sec-api.dev/pdufa/relacorilant) | CORT |  | completed | "Based on the positive outcome of the requested analyses, we resubmitted our NDA to the FDA on June 17, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1088856/000162828026069501/cort-20260930.htm)) |
| July 11, 2026 | [TAXOL® (paclitaxel) PDUFA date](https://sec-api.dev/pdufa/paclitaxel) | CORT | with platinum-resistant ovarian cancer | completed, approved | "•New Drug Application - FDA reviewing NDA for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, with a July 11, 2026 PDUFA date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort022426ex991pressrelease.htm)) |
| July 11, 2026 | [Lifyorli™ (relacorilant) PDUFA date](https://sec-api.dev/pdufa/relacorilant) | CORT | platinum-resistant ovarian cancer | scheduled | ""Our NDA for relacorilant in platinum-resistant ovarian cancer, which is now bolstered by the final overall survival results from our ROSELLA study, has a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort022426ex991pressrelease.htm)) |
| July 29, 2026 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/cort072926ex991pressrelease.htm)) |
| October 2026 | [Dazucorilant 300 mg primary completion](https://sec-api.dev/pdufa/dazucorilant) | CORT | Amyotrophic Lateral Sclerosis | delayed | "NCT05407324 (Dazucorilant in Patients With Amyotrophic Lateral Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05407324)) |
| Oct 2026 to Jan 2027 | [Dazucorilant 300 mg topline data readout](https://sec-api.dev/pdufa/dazucorilant) | CORT | Amyotrophic Lateral Sclerosis | scheduled | "NCT05407324 (Dazucorilant in Patients With Amyotrophic Lateral Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05407324)) |
| November 3, 2026 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm)) |
| December 2026 | [Lifyorli™ (relacorilant) primary completion](https://sec-api.dev/pdufa/relacorilant) | CORT | Cushing Syndrome | scheduled | "NCT03604198 (Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03604198)) |
| Dec 2026 to Mar 2027 | [Lifyorli™ (relacorilant) topline data readout](https://sec-api.dev/pdufa/relacorilant) | CORT | Cushing Syndrome | scheduled | "NCT03604198 (Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03604198)) |
| December 17, 2026 | [Lifyorli™ (relacorilant) NDA/BLA submission](https://sec-api.dev/pdufa/relacorilant) | CORT | with Cushing's syndrome | scheduled | "resubmission of our NDA for relacorilant for the treatment of patients with Cushing's syndrome and our expectation that the FDA will issue a decision on this NDA by December 17, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm)) |
| December 17, 2026 | [Lifyorli™ (relacorilant) PDUFA date](https://sec-api.dev/pdufa/relacorilant) | CORT | Cushing's syndrome - New Drug Application for relacorilant resubmitted | scheduled | "•Relacorilant for patients with Cushing's syndrome - Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm)) |
| September 2027 | [Lifyorli™ (relacorilant) primary completion](https://sec-api.dev/pdufa/relacorilant) | CORT | Adenocarcinoma; Carcinoma, Pancreatic Ductal | scheduled | "NCT07259317 (Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07259317)) |
| Sep to Dec 2027 | [Lifyorli™ (relacorilant) topline data readout](https://sec-api.dev/pdufa/relacorilant) | CORT | Adenocarcinoma; Carcinoma, Pancreatic Ductal | scheduled | "NCT07259317 (Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07259317)) |
| December 2027 | [Lifyorli™ (relacorilant) primary completion](https://sec-api.dev/pdufa/relacorilant) | CORT | Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms | scheduled | "NCT06906341 (Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06906341)) |
| Dec 2027 to Mar 2028 | [Lifyorli™ (relacorilant) topline data readout](https://sec-api.dev/pdufa/relacorilant) | CORT | Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms | scheduled | "NCT06906341 (Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06906341)) |

## Drugs

- [Corcept](https://sec-api.dev/pdufa/corcept): severe endocrinologic, oncologic, metabolic and neurologic disorders, cushing's syndrome, with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, hypertension secondary to hypercortisolism, platinum-resistant ovarian cancer, with endogenous hypercortisolism
- [Dazucorilant 300 mg](https://sec-api.dev/pdufa/dazucorilant): Amyotrophic Lateral Sclerosis
- [Miricorilant (cohort a)](https://sec-api.dev/pdufa/miricorilant-cohort-a): Nonalcoholic Steatohepatitis (NASH)
- [Nda219398](https://sec-api.dev/pdufa/nda219398): 
- [Lifyorli™ (relacorilant)](https://sec-api.dev/pdufa/relacorilant): endogenous hypercortisolism, platinum-resistant ovarian cancer, with cushing's syndrome, with platinum-resistant ovarian cancer in march 2026, hypercortisolism, cushing's syndrome - resubmitted new drug application prescription drug user fee act, Adenocarcinoma, Ovarian Cancer

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cort/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CORT catalysts: CORCEPT THERAPEUTICS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cort/catalysts

```bibtex
@misc{secapidev_companies_cort_catalysts_20261116,
  title        = {CORT catalysts: CORCEPT THERAPEUTICS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cort/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cort_catalysts_20261116","title":"CORT catalysts: CORCEPT THERAPEUTICS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cort/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
